Company Overview of Advanced Accelerator Applications S.A.
Advanced Accelerator Applications S.A., a radiopharmaceutical company, develops, produces, and commercializes molecular nuclear medicine (MNM) diagnostic and therapeutic products in France, Italy, Spain, Israel, Canada, the United States, and internationally. It provides positron emission tomography (PET) products, including Gluscan, a branded 18-fluorodeoxyglucose PET imaging agent that assists in the diagnosis of serious medical conditions primarily in oncology through assessing glucose metabolism; IASOflu, which images bone metastases; IASOdopa to diagnose Parkinson’s disease and tumors in various indications; and IASOcholine for diagnosing prostate cancer. The company also offers single-...
20 Rue Diesel
Saint Genis Pouilly, 01630
Founded in 2002
Key Executives for Advanced Accelerator Applications S.A.
Founder, Chief Executive Officer, President, Director and Member of R & D Steering Committee
Group Chief Financial Officer
Head of Clinical Development
Compensation as of Fiscal Year 2014.
Advanced Accelerator Applications S.A. Key Developments
Advanced Accelerator Applications S.A. Presents at BioEquity Europe 2015, May-19-2015 05:40 PM
May 8 15
Advanced Accelerator Applications S.A. Presents at BioEquity Europe 2015, May-19-2015 05:40 PM. Venue: InterContinental Vienna, Vienna, Austria.
Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Advanced Accelerator Applications S.A. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Advanced Accelerator Applications S.A. Announces Earnings Results for the First Nine Months of 2014
Nov 20 14
Advanced Accelerator Applications S.A. announced earnings results for the first nine months of 2014. For the nine months, sales of EUR 50,156,000 compared to EUR 38,919,000 a year ago. Operating income was EUR 2,199,000 compared to EUR 1,373,000 a year ago. Net income from continuing operations was EUR 1,135,000 compared to loss of EUR 2,038,000 a year ago. Adjusted EBITDA was EUR 9,668,000 compared to EUR 7,643.000 a year ago. Net operating cash-flow was EUR 9 million, an increase of 33% compared to the 6.7 million a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 8, 2015